Efficacy, Safety, and Tolerability of a Monoclonal Antibody to PCSK9 in Combination With a Statin in Patients With Hypercholesterolemia - LAPLACE-TIMI 57


The goal of the trial was to evaluate treatment with AMG 145, a monoclonal antibody, against proprotein convertase subtilisin/kexin type 9 (PCSK9) compared with placebo among stable patients with hypercholesterolemia treated with a statin.

PCSK9 binds low-density lipoprotein cholesterol (LDL-C) receptors and targets them for degradation.